ClinicalTrials.gg
RecruitingNCT07185256BIRD-1Updated Sep 24, 2026

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

A Phase 1/2 interventional study of OPGx-BEST1 in ARB, BVMD and Autosomal-Dominant Bestrophinopathy, sponsored by Opus Genetics, Inc. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Opus Genetics, Inc · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main questions it aims to answer are:

Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for 5 years post-injection, in participants with BVMD or ARB.

A second question it aims to answer is identification of the most appropriate dose strength of OPGx-BEST1 for clinical development.

Evaluate the efficacy of single injection of OPGx-BEST1 in one eye for 5 years post-injection.

What medical problems do participants have when taking drug OPGx-BEST1?

Read the detailed description

This is a Phase 1b/2a, open-label, dose-exploring, safety and tolerability basket study of a single subretinal injection of OPGx-BEST1 in one eye of adult participants with ARB or BVMD due to BEST1 mutations.

OPGx-BEST1 has been bioengineered to include a transgene expression cassette with a codon-optimized, full-length hBEST1 gene under the control of an RPE-specific promoter. The vector genome contains inverted terminal repeats flanking an expression cassette containing the VMD2 promoter, full-length BEST1 ORF followed by SV 40 and bGH polyadenylation signal sequences, and lastly includes a kanamycin resistance gene. The Kozak sequence (upstream of the start codon) enhances the translation from the correct initiation codon. Selection of the VMD2 promoter was done to restrict the expression to the target cell type and drive expression levels comparable to those in photoreceptors. This intervention is a one-time injection.

Two vector doses are proposed for evaluation: 1.5E9 vg/eye (Cohort 1) and 4.5E9 vg/eye (Cohort 2). A minimum of 5 evaluable participants will be treated at each dose level, starting with a sentinel participant in Cohort 1. An Independent Data Monitoring Committee (IDMC) will evaluate safety 30 days after treatment of the sentinel participant before the remaining 4 participants in Cohort 1 are eligible for treatment. After the last participant has completed the Month 3 visit, the IDMC will review all Cohort 1 data and determine whether to initiate enrollment in Cohort 2 or adjust the dose escalation scheme.

Each participant will have a Screening visit and two-part Baseline visit. On Day 1 (Visit 4), participants will undergo vitrectomy with subretinal injection of OPGx-BEST1 at the preassigned dose. Participants will return for follow-up on Day 2, Day 7, Day 14, Day 30, and Day 45 following IMP administration (Visits 5-9). Participants will also return 3 and 6 months following IMP administration (Visits 10-11) and 1, 1.5, 2, 3, 4, and 5 years following IMP administration (Visits 12-17).

Post-IMP administration, safety and efficacy outcomes will be evaluated for 5 years.

In addition to the primary objectives of establishing IMP safety and tolerability and identifying the most appropriate dose strength, the study will evaluate the preliminary efficacy of OPGx-BEST1 and characterize the immunogenic effects of administration. A central reading center will provide standardized evaluation of select imaging data. Analysis of results will include treatment-eye comparisons of visual function post-administration of OPGx-BEST1 to baseline visual function.

02

Conditions studied

  • ARB
  • BVMD
  • Autosomal-Dominant Bestrophinopathy
  • Best Vitelliform Macular Dystrophy

Keywords

  • Bestrophinopathy
  • BVMD
  • ARB
  • OPGx-BEST1
  • Best vitelliform macular dystrophy
  • Autosomal-Dominant Bestrophinopathy
03

In context

Lead sponsor

Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Individuals who meet all the following criteria will be eligible to participate in the study:

  1. Provide to study assessments.
  2. Able and willing to comply with all study assessments for the duration of the study.
  3. ≥18 years old.
  4. ETDRS BCVA measured with standard testing distances:

    1. For the sentinel participant in each cohort, ≤20 letters (Snellen equivalent of 20/200 [1.30 logMAR] or worse)
    2. For subsequent participants in the same cohort, 65 to 20 letters inclusive (Snellen equivalent of 20/50 [0.40 logMAR] to 20/200 [1.30 logMAR]).
  5. Genetic confirmation on chromosome 11q12-q13.1 of BVMD or ARB with a BEST1 genetic test or IRD panel test including a BEST1 variant test, by a Clinical Laboratory Improvement Amendments (CLIA) or European certified laboratory. If available test result is more than 15 years old, confirmation testing will be performed at Visit 1, with results needed by Visit 3.
  6. Confirmation of one disease-causing (pathogenic or likely pathogenic, autosomal-dominant) variant in the BEST1 gene for BVMD, as listed in the IB, or two variants for ARB per American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) variant interpretation.
  7. BVMD: Clinical phenotype and diagnosis consistent with advanced BVMD with active subretinal fluid or vitelliform material.
  8. ARB: Clinical phenotype and diagnosis consistent with ARB.

Exclusion criteria

Exclusion Criteria:

Individuals who meet any of the following criteria will not be eligible to participate in the study.

  1. Women of (WOCBP) who are pregnant, lactating, and/or unwilling to use effective from Screening through 1 year after IMP administration. See Section 13.3 (Appendix 3) for contraception guidelines.
  2. Men who are unwilling to use adequate contraception from Screening through 180 days after IMP administration. See Section 13.3 (Appendix 3) for contraception guidelines.
  3. Have a pre-existing eye condition or complicating systemic disease that could preclude the planned surgery (e.g., individuals who are , on continuous systemic immunosuppressive treatment or anticipate a need to initiate it for non-study reasons, or unable to take the concomitant immuno-suppressive regimen necessary for IMP administration).
  4. Have a history of disease that may preclude the individual from study participation (e.g., other bestrophinopathy, such as AOFVD or ADVIRC) or that may interfere with or preclude outcome measure testing as described in the protocol.
  5. Have previously received gene therapy of any kind.
  6. Presence of active choroidal neovascularization (CNV) that, in the opinion of the Investigator, affects vision or may require treatment.
  7. Presence of subretinal fibrosis that may significantly limit improvement in visual acuity.
  8. Have an epiretinal membrane that may require surgical intervention.
  9. Have undergone tube surgery for glaucoma at any time or have glaucoma that has been unstable within the past 4 years. Note: Prior incisional surgery (e.g., trabeculectomy and iridotomy) is not exclusionary.
  10. Had intraocular surgery within 90 days prior to planned IMP administration or have active inflammation at Screening resulting from prior ocular surgery.
  11. Have used any drug or device within 90 days prior to planned IMP administration or plan to participate in another drug or device study during the same period as the current study.
  12. Have received a vaccination within 6 weeks prior to planned IMP administration or plan to be vaccinated within 6 months after IMP administration.
  13. Have received anticoagulant therapy within 2 weeks prior to planned IMP administration.
  14. Have active macular neovascularization as determined by OCT-A.
  15. Are incapable of performing visual function testing for reasons other than poor vision.
  16. Have any to the concomitant regiment proscribed in the protocol.
  17. Have any other condition (ocular, medical, or psychological) that would not allow the individual to complete follow-up examinations during the study and/or, in the opinion of the Investigator, makes it hazardous or unsuitable for the individual to participate in the study.
  18. Have a known history of to constituents or in the pharmaceutical formulation of the IMP.
  19. Have a known infection of (HIV), or C virus, or herpes simplex virus.
  20. Are an employee of the Sponsor or a relative of the Investigator or investigative site staff.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    OPGx-BEST1

    OPGx-BEST1, 1.5E9 vg/eye injected one time subretinally

    Genetic: OPGx-BEST1

Interventions

  • GeneticOPGx-BEST1

    Experimental Genetic Therapy

06

What researchers measure

Primary outcomes

  1. Number of dose-limiting toxicity (DLT) events at the dose tested

    Number of dose-limiting toxicity (DLT) events, defined as any ≥Grade 3 toxicity that occurs within 90 days after IMP administration based on the National Cancer Institute common toxicity criteria

    Time frame: 5 years

  2. Number and severity of procedure-related adverse events

    Number and severity of adverse events related to the administration of OPGx-BEST1 involving pars plana vitrectomy and subretinal injection under general anesthesia

    Time frame: 5 years

  3. Number and severity of adverse events related to OPGx-BEST1

    Number and severity of adverse events considered related to the study drug, OPGx-BEST1

    Time frame: 5 years

Secondary outcomes

  1. Changes from baseline in retinal morphology assessed by spectral-domain optical coherence tomography

    Changes from baseline in retinal morphology assessed by spectral-domain optical coherence tomography

    Time frame: 5 years

  2. Changes from baseline in retinal morphology assessed by 55 degree fundus autofluorescence (FAF)

    Changes from baseline in retinal morphology assessed by 55 degree fundus autofluorescence (FAF)

    Time frame: 5 years

  3. Changes from baseline in retinal morphology assessed by ultra-wide angle autofluorescence (FAF)

    Changes from baseline in retinal morphology assessed by ultra-wide angle autofluorescence (FAF)

    Time frame: 5 years

  4. Changes from baseline in neovascularization assessed by optical coherence tomography

    Changes from baseline in neovascularization assessed by optical coherence tomography angiography

    Time frame: 5 years

  5. Changes from baseline in retinal sensitivity

    Changes from baseline in retinal sensitivity assessed by microperimetry

    Time frame: 5 years

  6. Changes from baseline in best corrected visual acuity

    Changes from baseline in best corrected visual acuity letter score as measured by Early Treatment Diabetic Retinopathy Stuidy (ETDRS) charts

    Time frame: 5 years

  7. Changes from baseline in low luminance visual acuity

    Changes from baseline in low luminance visual acuity assessed by ETDRS charts

    Time frame: 5 years

  8. Changes from baseline in participant-reported outcomes

    Changes from baseline in participant-reported outcomes assessed by the Michigan Retinal Degeneration Questionnaire

    Time frame: 5 years

07

Study locations

4 of 5 sites recruiting
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
    Recruiting
    • Hillary Schwartz-Gale · Contacthschwartz@chla.usc.edu · 323-361-1004
    • Aaron Nagiel, MD · Principal investigator
  • Vitreo Retinal Associates
    Gainsville, Florida 34481, United States
    Not yet recruiting
    • Hailey Ahrens · Contacthailey@vra-pa.com · 352-300-4212
    • Christine Kay, MD · Principal investigator
  • Harkness Eye Institute, CColumbia University Irving Medical Center
    New York, New York 10032, United States
    Recruiting
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
    Recruiting
    • Cincinnati Eye Institute Clinical Research Department · Contactcvp-research@cvphealth.com · 513-569-3688
    • Robert Sisk, MD · Principal investigator
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Aug 2030, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Sep 22, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Aug 2030
CompletionEst.
Aug 2030
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185256
Lead sponsor
Opus Genetics, Inc
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Sep 25, 2025
Primary completion
Aug 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Sep 24, 2026

Study contacts

Study Director
Contact
ct.gov_inquiries@opusgtx.com
984-884-6030

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion